XSpray announces positive data from dog studies with their novel formulation strategy for PKIs.
XSpray Announces Major Advance in the Formulation of Challenging Oral Protein Kinase Inhibitors (PKI)
October 10th, 2012XSpray and Cerbios-Pharma announce partnership on the use of XSpray’s RightSize™ technology
September 4th, 2012XSpray will be the technology provider and Cerbios will be the API manufacturer.
XSpray receives innovation grant for nanoparticle technology
December 6th, 2010The SEK 2.3 million grant from Vinnova will be used to expand the company’s nanoparticle technology.
XSpray strengthens patent portfolio for breakthrough particle production technology
November 4th, 2010US Patent and Trademark Office has granted patent.
XSpray launches GMP production facility
August 20th, 2009Providing customers with high quality particulate manufacturing meeting US and EU regulatory standards.
Xspray expands to meet pharma’s interest in its ground-breaking particle production technology
April 20th, 2009The Company has doubled both its personnel and lab space in order to meet growing interest.
Xspray boosts customer value with solid state characterization services
December 1st, 2008Expanded service offering now includes sophisticated solid state characterization and analysis capabilities.
Xspray appoints Dr. Mikael Bisrat as Chief Scientific Officer
August 1st, 2008New appointment supports development plans as pharma companies begin evaluating RightSize™ technology.
Xspray™ Microparticles AB announces financing to take RightSize™ Manufacture technology to GMP
November 9th, 2007GMP Manufacture using RightSize™ Manufacture Technology will enable supercritical fluid production of pharmaceuticals.
Xspray Microparticles AB Appoints Gérald Jesson as V.P operations
October 15th, 2007New V.P Appointment Supports the development of SCF RightSize™ Manufacture Technology.